Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563917 | 1.00 | PNMT (0.62) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL12136140 | 1.00 | PNMT (0.62) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL29968153 | 1.00 | PNMT (0.62) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| Hydrochloric Acid SCHEMBL30559539 | 0.98 | PNMT (0.60) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL7694750 | 0.87 | TAAR1 (0.55) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL24152546 | 0.86 | TAAR1 (0.73) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL13387614 | 0.86 | TAAR1 (0.73) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL4693239 | 0.86 | TAAR1 (0.50) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL598282 | 0.84 | TAAR1 (0.52) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL3126846 | 0.84 | TAAR1 (0.48) | PNMTTAAR1SLC6A2MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017098533-A2 | PROCESS FOR PREPARATION OF LISDEXAMPHETAMINE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-15 | — | — | WO | disclosed |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20140155369-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | ASTELLAS PHARMA INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SHIRAI JUNYA (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155369-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | ADRA2C, HTR2C, HTR3A | PNMT 26/4885TAAR1 445/4885SLC6A2 57/4885 |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | PNMT 113/4885TAAR1 100/4885SLC6A2 36/4885 |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | HTR2A, HTR2C, HTR3A | PNMT 386/4885TAAR1 427/4885SLC6A2 279/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | PNMT 113/4885TAAR1 100/4885SLC6A2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.